| Matthew R Lindaman, DO | |
|
2300 53rd Ave, Suite 100, Bettendorf, IA 52722-7564 | |
| (563) 322-0971 | |
| (563) 324-0615 |
| Full Name | Matthew R Lindaman |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 29 Years |
| Location | 2300 53rd Ave, Bettendorf, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053390914 | NPI | - | NPPES |
| 1214528 | Medicaid | IA | |
| IA01A7 | Other | IA | JOHN DEERE FAMILY |
| P00195719 | Other | IA | RR MEDICARE |
| IA01A8 | Other | IA | JOHN DEERE FAMILY |
| 35021 | Other | MIDLANDS CHOICE | |
| 37771 | Other | IA | WELLMARK |
| 92233 | Other | IL | WELLMARK |
| IL01A9 | Other | IL | JOHN DEERE FAMILY |
| 153910 | Other | IA HEALTH SOLUTIONS | |
| IA01A5 | Other | IA | JOHN DEERE FAMILY |
| IA01A6 | Other | IA | JOHN DEERE FAMILY |
| 063409 | Other | HEALTH ALLIANCE | |
| 37770 | Other | IA | WELLMARK |
| 8121085 | Other | IL | BCBS |
| IA01B1 | Other | IA | JOHN DEERE FAMILY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 3309 (Iowa) | Primary |
| 207X00000X | Orthopaedic Surgery | 036102562 (Illinois) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Genesis Vna | Bettendorf, IA | Home health agency |
| Genesis Medical Center-davenport | Davenport, IA | Hospital |
| Genesis Medical Center-dewitt | Dewitt, IA | Hospital |
| Jackson County Regional Health Center | Maquoketa, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ora Orthopedics Pc | 6406741784 | 102 |
| Ora Orthopedics Pc | 6406741784 | 102 |
News Archive
Humana Inc. today announced it has signed a definitive agreement to purchase Concentra Inc., a privately held health care company based in Addison, Texas, for approximately $790 million in cash. Through its affiliated clinicians, Concentra delivers occupational medicine, urgent care, physical therapy and wellness services to workers and the general public from more than 300 medical centers in 42 states.
Using the VAP Cholesterol Test from Atherotech, Inc., University of Maryland researchers have found an association between a rare gene mutation and heart protection.
With electronic medical records creating an ideal source of data to inform quality care and new discovery, a key question emerges: How much say should patients have in how their data is used?
As scientists gain insights into which genes drive diseases, they are pursuing the next logical question: Can gene editing technologies be developed to treat or even cure those diseases? Much of that effort has focused on developing technologies such as CRISPR-Cas9, a protein-based system.
Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.
› Verified 9 days ago
| Entity Name | Ora Orthopedics Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962481861 PECOS PAC ID: 6406741784 Enrollment ID: O20040407001036 |
News Archive
Humana Inc. today announced it has signed a definitive agreement to purchase Concentra Inc., a privately held health care company based in Addison, Texas, for approximately $790 million in cash. Through its affiliated clinicians, Concentra delivers occupational medicine, urgent care, physical therapy and wellness services to workers and the general public from more than 300 medical centers in 42 states.
Using the VAP Cholesterol Test from Atherotech, Inc., University of Maryland researchers have found an association between a rare gene mutation and heart protection.
With electronic medical records creating an ideal source of data to inform quality care and new discovery, a key question emerges: How much say should patients have in how their data is used?
As scientists gain insights into which genes drive diseases, they are pursuing the next logical question: Can gene editing technologies be developed to treat or even cure those diseases? Much of that effort has focused on developing technologies such as CRISPR-Cas9, a protein-based system.
Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew R Lindaman, DO 2300 53rd Ave, Suite 100, Bettendorf, IA 52722-7564 Ph: (563) 322-0971 | Matthew R Lindaman, DO 2300 53rd Ave, Suite 100, Bettendorf, IA 52722-7564 Ph: (563) 322-0971 |
News Archive
Humana Inc. today announced it has signed a definitive agreement to purchase Concentra Inc., a privately held health care company based in Addison, Texas, for approximately $790 million in cash. Through its affiliated clinicians, Concentra delivers occupational medicine, urgent care, physical therapy and wellness services to workers and the general public from more than 300 medical centers in 42 states.
Using the VAP Cholesterol Test from Atherotech, Inc., University of Maryland researchers have found an association between a rare gene mutation and heart protection.
With electronic medical records creating an ideal source of data to inform quality care and new discovery, a key question emerges: How much say should patients have in how their data is used?
As scientists gain insights into which genes drive diseases, they are pursuing the next logical question: Can gene editing technologies be developed to treat or even cure those diseases? Much of that effort has focused on developing technologies such as CRISPR-Cas9, a protein-based system.
Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.
› Verified 9 days ago
Michael T Pyevich, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2300 53rd Ave, Suite 100, Bettendorf, IA 52722 Phone: 563-322-0971 Fax: 563-324-0615 | |
Ryan Travis Pokorney, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2300 53rd Ave, Bettendorf, IA 52722 Phone: 563-322-0971 Fax: 563-324-0615 | |
Dr. Myles Julian Luszczyk, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2300 53rd Ave, Suite 100, Bettendorf, IA 52722 Phone: 563-322-0971 Fax: 563-324-0615 | |
Dr. Ryan Patrick Dunlay, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2300 53rd Ave, Suite 100, Bettendorf, IA 52722 Phone: 563-322-0971 Fax: 563-324-0615 | |
Joseph G Martin, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2300 53rd Ave, Suite 100, Bettendorf, IA 52722 Phone: 563-322-0971 Fax: 563-324-0615 | |
Mohammed Hussain, Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2300 53rd Ave Ste 100, Bettendorf, IA 52722 Phone: 563-322-0971 |